Isabella Feierberg

Learn More
A major challenge in drug design is to obtain compounds that bind selectively to their target receptors and do not cause side-effects by binding to other similar receptors. Here, we investigate strategies for applying COMBINE (COMparative BINding Energy) analysis, in conjunction with PIPSA (Protein Interaction Property Similarity Analysis) and ligand(More)
Human H-PGDS has shown promise as a potential target for anti-allergic and anti-inflammatory drugs. Here we describe the discovery of a novel class of indole inhibitors, identified through focused screening of 42,000 compounds and evaluated using a series of hit validation assays that included fluorescence polarization binding, 1D NMR, ITC and chromogenic(More)
High-throughput screening (HTS) is widely used in the pharmaceutical industry to identify novel chemical starting points for drug discovery projects. The current study focuses on the relationship between molecular hit rate in recent in-house HTS and four common molecular descriptors: lipophilicity (ClogP), size (heavy atom count, HEV), fraction of(More)
In the early stages of a drug discovery project it is often necessary to narrow down the search space for potential new leads substantially [1,2]. This crucial step identifies a set of molecules (a hit series) that have a high likelihood of being relevant to the drug discovery project. In many cases high throughput screening (HTS) is used to test (in-vitro)(More)
High throughput screening (HTS) is one of the most prominent techniques used in the beginning stages of a drug discovery programme to identify those few hit compounds that can be used as starting points in subsequent studies [1,2]. However, an HTS experiment often entails a very data-intensive and challenging hit prioritization process that yields the(More)
  • 1